Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
SAN DIEGO and CALGARY, Alberta, June 30, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer.
Mr. Aromando most recently served as Chief Operating Officer at Ambrx Biopharma, where his contributions were instrumental in the $2 billion acquisition of the San Diego-based biotech by Johnson & Johnson. In his role at Oncolytics, Mr. Aromando will be responsible for leading global business development. He will also be directly involved with developing corporate, clinical and regulatory strategies. Among his key priorities will be optimizing the value of the Company's expansive suite of promising clinical data for pelareorep in multiple tumor types, including pancreatic, breast, and anal cancers.
'Andrew's experience will be invaluable as we pursue aggressive clinical and business development strategies to maximize the value of pelareorep on an accelerated timeline,' said Jared Kelly, Chief Executive Officer of Oncolytics. 'He is a proven industry leader with a successful track record of navigating complex transactions and partnerships and an outstanding addition to our executive team.'
Mr. Aromando added, 'I'm thrilled to join Oncolytics at such a pivotal moment in its evolution. With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term.'
Mr. Aromando has over 30 years of experience in the life sciences industry. He has served more than 20 years in C-level positions at leading oncology-focused biopharma companies and global service providers. His senior executive roles at these companies were centered on strategic planning, corporate development, portfolio optimization, and product commercialization. He earned his BA from The College of New Jersey and MA from Rutgers University.
As a material inducement to Mr. Aromando's appointment as Chief Business Officer, and in accordance with NASDAQ Listing Rule 5635(c)(4), Mr. Aromando has been awarded an initial stock option grant exercisable for 750,000 shares with an exercise price of CAD$0.93, vesting equally over three years with a term of 5 years from the date of grant. The Company also granted Mr. Aromando 500,000 restricted stock units, which vest upon the Company entering into a definitive agreement for certain transactions providing for the acquisition of the Company or the exclusive license of pelareorep.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning 'cold' tumors 'hot' -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @ oncolytics.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as 'forward-looking statements'). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our plans, objectives and strategies; our focus on advancing pelareorep into registration enabling studies; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Company Contact
Jon Patton
Director of IR & Communication
[email protected]
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
[email protected]
Media Contact for Oncolytics
Owen Blaschak
LifeSci Communications
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/oncolytics-biotech-appoints-former-ambrx-executive-as-chief-business-officer-to-drive-business-development-strategy-302494308.html
SOURCE Oncolytics Biotech® Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
41 minutes ago
- Bloomberg
Enbridge Dispute With Michigan Over Oil Pipeline Goes to US Supreme Court
Enbridge Inc. 's long-simmering dispute with the state of Michigan over an oil pipeline that runs under the Straits of Mackinac is headed for the US Supreme Court after years of legal battles and the intervention of Canada's government. The highest US court agreed to hear a case concerning whether Michigan's efforts to shut down the so-called Line 5 oil pipeline belong in federal or state court. Enbridge wants the case heard by the federal court, arguing that the dispute deals with the foreign relations between Canada and the US. Canada has invoked a 1977 treaty to try and prevent Michigan from shutting the line, which supplies oil to refineries in Ontario and Quebec.
Yahoo
an hour ago
- Yahoo
Lululemon sues Costco, alleging the discount retailer copied its designs
Lululemon is suing Costco, accusing the discount retailer of selling "confusingly similar" replicas of its jackets, sweatshirts and pants. In a lawsuit filed Friday in the U.S. District Court for the Central District of California, the athletic and lifestyle apparel company claims that certain Costco products imitate its own designs so closely that it constitutes "trade dress" infringement, which occurs when a product mimics another so closely that it confuses consumers. The apparel company claims that Costco's "knockoff" designs, or product "dupes," violate trademark law because "some customers incorrectly believe these infringing products are authentic Lululemon apparel." In other cases, "customers specifically purchase the infringing products because they are difficult to distinguish from authentic Lululemon products," the lawsuit alleges. "Indeed, one of the purposes of selling 'dupes' is to confuse consumers at the point-of-sale and/or observers post-sale into believing that the 'dupes' are Plaintiffs' authentic products when they are not," the lawsuit alleges. Lululemon refers to itself in the lawsuit as a "path-breaking" apparel company that has set a new standard for performance athletic wear, adding that its "construction techniques" and "strategic fits" help it stand out to consumers. Reached for comment, the Vancouver, Canada-based company said it fiercely defends its products. "As an innovation-led company that invests significantly in the research, development and design of our products, we take the responsibility of protecting and enforcing our intellectual property rights very seriously and pursue the appropriate legal action when necessary," a Lululemon company spokesperson told CBS MoneyWatch. Costco did not immediately respond to CBS MoneyWatch's request for comment. While copycat products can be so poorly constructed and designed that they pose no threat to the originals, Costco's dupes have caused a stir for their verisimilitude to the authentic Lululemon goods. A January headline in The Washington Post read, "Is that hoodie Lululemon or a Costco dupe? No one has to know but you." On social media, users post images and videos of Costco athletic-wear products with the hashtag #luludupe or #lululemondupes. What items does Lululemon say Costco copies? The items at the center of the lawsuit include Lululemon's popular "Scuba" hoodies and sweatshirts, its "Define" jackets, and "ABC" stretch pants — that resemble khakis pants — for men. Lululemon's Scuba hoodie retails for $118, while its Define jacket sells for $128. The ABC pants cost $128. According to Lululemon, Costco's infringing products include: Danskin Ladies Half-Zip HoodieDanskin Half-Zip PulloverJockey Ladies Yoga JacketSpyder Women's Yoga JacketHi-Tec Men's Scuba Full ZipKirkland 5 Pocket Performance Pant Lululemon is seeking damages in the form of lost profits, and for Costco to cease the manufacturing and distribution of products Lululemon claims violate trade dress. Video shows Arizona police rescuing baby left alone for days Saving money vs. saving lives Colorado firebombing victim dies, suspect to be charged with 1st-degree murder
CBS News
2 hours ago
- CBS News
Lululemon sues Costco, alleging the retailer copied its designs
Lululemon is suing Costco, accusing the discount retailer of selling "confusingly similar" replicas of its jackets, sweatshirts and pants. In a lawsuit filed Friday in the U.S. District Court for the Central District of California, the athletic and lifestyle apparel company claims that certain Costco products imitate its own designs so closely that it constitutes "trade dress" infringement, which occurs when a product mimics another so closely that it confuses consumers. The apparel company claims that Costco's "knockoff" designs, or product "dupes," violate trademark law because "some customers incorrectly believe these infringing products are authentic Lululemon apparel." In other cases, "customers specifically purchase the infringing products because they are difficult to distinguish from authentic Lululemon products," the lawsuit alleges. "Indeed, one of the purposes of selling 'dupes' is to confuse consumers at the point-of-sale and/or observers post-sale into believing that the 'dupes' are Plaintiffs' authentic products when they are not," the lawsuit alleges. Lululemon refers to itself in the lawsuit as a "path-breaking" apparel company that has set a new standard for performance athletic wear, adding that its "construction techniques" and "strategic fits" help it stand out to consumers. Reached for comment, the Vancouver, Canada-based company said it fiercely defends its products. "As an innovation-led company that invests significantly in the research, development and design of our products, we take the responsibility of protecting and enforcing our intellectual property rights very seriously and pursue the appropriate legal action when necessary," a Lululemon company spokesperson told CBS MoneyWatch. Costco did not immediately respond to CBS MoneyWatch's request for comment. While copycat products can be so poorly constructed and designed that they pose no threat to the originals, Costco's dupes have caused a stir for their verisimilitude to the authentic Lululemon goods. A January headline in The Washington Post read, "Is that hoodie Lululemon or a Costco dupe? No one has to know but you." On social media, users post images and videos of Costco athletic-wear products with the hashtag #luludupe or #lululemondupes. What items does Lululemon say Costco copies? The items at the center of the lawsuit include Lululemon's popular "Scuba" hoodies and sweatshirts, its "Define" jackets, and "ABC" stretch pants — that resemble khakis pants — for men. Lululemon's Scuba hoodie retails for $118, while its Define jacket sells for $128. The ABC pants cost $128. According to Lululemon, Costco's infringing products include: Danskin Ladies Half-Zip Hoodie Danskin Half-Zip Pullover Jockey Ladies Yoga Jacket Spyder Women's Yoga Jacket Hi-Tec Men's Scuba Full Zip Kirkland 5 Pocket Performance Pant Lululemon is seeking damages in the form of lost profits, and for Costco to cease the manufacturing and distribution of products Lululemon claims violate trade dress.
